Alzamend Neuro(ALZN)

Focus: Alzamend Neuro is a public biotechnology company focused on Alzheimer's disease treatment, headquartered in Atlanta with a pipeline of early-stage candidates.

Neurology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Alzamend Neuro

AI assessmentNot Hiring

No open roles listed right now. Follow Alzamend Neuro to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AL001

Alzheimer's Disease

Phase 1/2

Clinical Trials (3)

NCT07540338A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

Phase 1/2

Help build intelligence for Alzamend Neuro

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a focused Alzheimer's pipeline with two Phase 1/2 programs in an undercrowded therapeutic area with high unmet medical need
Public company status provides liquidity and scale benefits without the constraints of early-stage funding uncertainty
Opportunity to contribute to neurology research with minimal headcount competition (current hiring frozen)

Watch Out For

Severe cash crisis: only $376K in cash (FY 2025) against $9.9M net loss, with 93% cash burn year-over-year decline
Zero active job openings and no pipeline programs beyond Phase 1/2, indicating minimal near-term growth catalysts or hiring runway
Pre-revenue stage with $6M R&D spend (FY 2025) and deteriorating financial position raises material viability risk

Generated by Claude from Alzamend Neuro's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT05363293Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects

Phase 1/2

NCT06921590A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

Phase 1

ALZN002

Alzheimer's Disease

Phase 1/2

Clinical Trials (1)

NCT05834296Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2008

Portfolio: 4 clinical trials

Top TAs: Neurology

Publications: 1 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Neurology

3 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$6M13%

Net Income

-$10M

Cash

$376K

Source: SEC 10-K Filing

Research Publications(1)

Recent peer-reviewed publications with author affiliations at this company

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

Nature medicine

2026

PMID:41714746

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Alzamend Neuro(ALZN)

About Alzamend Neuro

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Alzamend Neuro(1)

Open Jobs (0)

Financials (FY2025)

Research Publications(1)